Outbreaks of a deadly, sexually transmitted disease confound health officials, whose obstacles include drug shortages, uneducated doctors and gangs

Quick Read

John Zhang, a New York fertility doctor, wanted to push the boundaries of science and fertility by giving women at risk of passing on serious genetic conditions a chance at healthy kids through an IVF technique that uses the DNA of three people

Quick Read

When a receptionist hands out a form to fill out at a doctor’s office, the questions are usually about medical issues: What’s the visit for? Are you allergic to anything? Up to date on vaccines? But some health organizations are now asking much more general questions: Do you have trouble paying your bills? Do you feel safe at home? Do you have enough to eat?

Quick Read

Stacey Lee, an assistant professor at JHU’s Carey Business School, suggests a more transparent process for patients

Quick Read

The controversial practice has been standard in many teaching hospitals for decades, its safety and ethics largely unquestioned and its existence unknown to those most affected: people undergoing surgery

Quick Read

There can’t be many people in the UK who haven’t heard of Charlie Gard. He’s a little boy with mitochondrial disease who is on life support. His parents want to send him to the US for experimental treatment; the UK courts have ruled on medical advice that the treatment does not show sufficient promise. Medics think Charlie can’t be helped. His desperate parents claim otherwise, citing the support of 7 international doctors and a 350,000 strong petition

Quick Read

The highly anticipated court hearing comes a day after Connie Yates and Chris Gard made a public appearance to state that their son “deserves a chance” to be taken to the United States for an experimental treatment that could potentially improve his condition

Quick Read

If you were dying, surely you would grasp at any chance medicine might offer you. Recently, there has been a lot of effort at the state and federal levels to try to increase patient access to experimental drugs. The approach has been to cut the FDA out of what is known as “compassionate use”

Quick Read